Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment

Non-small Cell Lung Cancer (NSCLC) Clinical Trial

Official title:

Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields（EFE-P100） Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1(PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05661240
• Other study ID #: P100-NSCLC2
• Status: Not yet recruiting
• Phase: Phase 2/Phase 3
• Start date: December 20, 2022
• Est. completion date: July 31, 2025

Study information

• Verified date: December 2022
• Source: Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
• Contact: Zhou
• Phone: 02165115006
• Email: caicunzhou[@]yahoo.com.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The tumor treating fields（EFE-P100）generates alternating electric field during operation, and the tumor treating fields（EFE-P100）has a specific frequency and a specific field intensity. The tumor treating fields（EFE-P100）patch acts on the corresponding part of the patient and prevents the mitosis of tumor cells. This study was divided into two phases including phase II and phase III clinical trials. The main purpose of phase II clinical trial is to evaluate the safety of tumor treating fields（EFE-P100） combined with docetaxel injection in the second-line treatment of stage IV non-small Cell Lung Cancer (NSCLC) patients who failed after platinum-containing chemotherapy and anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) antibody treatment. The main purpose of phase III clinical trial is to compare the efficacy of tumor treating fields（EFE-P100） combined with docetaxel injection and docetaxel injection alone in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) patients who failed after platinum-containing chemotherapy and anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) antibody treatment.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 348
• Est. completion date: July 31, 2025
• Est. primary completion date: May 25, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Age =18 and =80, both sexes;

2. Expected survival time =3 months;

3. Non-small cell lung cancer was confirmed histologically or cytologically and classified as stage IV NSCLC according to the American Joint Committee on Cancer(AJCC)of eighth edition.

4. Imaging progression (according to RECIST V1.1 criteria) or clinical progression during previous anti-PD - (L) 1 antibody and platinum-containing therapy or after treatment;

• Neoadjuvant or adjuvant therapy, such as disease recurrence or progression =6 months after the end of treatment, counted as first-line treatment; - Prior treatment with at least 2 cycles of anti-PD - (L) 1 antibody, allowed as a single agent or in combination with platinum-based chemotherapy.

5. At least one measurable or evaluable lesion according to RECIST version 1.1;

6. ECOG 0-1;

7. Concomitant Adverse Event(AE) after previous treatment should return to normal level or Common Terminology Criteria for Adverse Events(CTCAE) grade 1;

8. Voluntarily sign informed consent.

Exclusion Criteria:

1. Epidermal growth factor receptor(EGFR)-activating mutations or Anaplastic Lymphoma Kinase(ALK) fusion gene was positive; However, if squamous non-small cell lung cancer has not been tested before, it can no longer be tested and allowed to be enrolled.

2. Untreated brain metastases, or with meningeal metastases, spinal cord compression, etc. Patients who had received previous treatment for brain metastases and were asymptomatic if they had been stable for at least 4 weeks on imaging before randomization and had stopped systemic hormone therapy (dose >10mg/ day prednisone or other equivalent hormone) for more than 2 weeks were eligible.

3. Severe bone injury due to bone metastases, including severe bone pain that is poorly controlled, pathologic fractures of major sites that have occurred within the last 6 months or are expected to occur in the near future.

4. Previous docetaxel therapy or docetaxel-containing combination therapy;

5. There are contraindications to docetaxel treatment or a known severe allergy to docetaxel;

6. A history of diagnosis of a tumor other than small-cell lung cancer and antitumor therapy within 5 years prior to enrollment, excluding treated stage I prostate cancer, cervical or uterine cancer in situ, breast cancer in situ, and non-melanoma skin cancer;

7. Abnormal bone marrow, heart, liver and kidney function: A. Neutrophil count <1.5×109/L, platelet count <100×109/L, hemoglobin <90 g/L; TBiL> upper normal value (ULN); AST and/or ALT>2.5×ULN; ALP>2.5×ULN (>5×ULN if bone metastases are present); C. Serum creatinine >1.5×ULN; Creatinine clearance rate <50 mL/min;

8. A history of severe cardiovascular disease, including second/third degree heart block; Severe ischemic heart disease; Poor control of hypertension; New York Heart Association (NYHA) class II or worse congestive heart failure (mild physical activity limitation; Comfortable at rest, but normal activities can cause fatigue, palpitations, or difficulty breathing);

9. Patients who required systemic corticosteroid (other corticosteroid at a dose of more than 10mg prednisone per day or an equivalent physiologic dose) or other immunosuppressive agents within 14 days prior to enrollment or during the study period were eligible for enrollment if: A. The use of topical or inhaled glucocorticoids is permitted; B. Allow short-term (=7 days) use of glucocorticoids for the prevention or treatment of non-autoimmune allergic diseases;

10. If she had severe infection before the first treatment, the investigator judged that she was not suitable to participate in this study.

11. A history of human immunodeficiency virus (HIV) infection (known HIV1/2 antibody positive);

12. The presence of active hepatitis B, active hepatitis C, or other active infections that the investigator determines may affect the patient's treatment;

13. There is a definite history of neurological or psychiatric disorders (e.g., epilepsy, dementia) or drug use or alcohol abuse within the last year that may affect trial compliance;

14. Symptomatic ascites, pleural effusion, pericardial effusion, etc., except those who are stable after clinical treatment (including therapeutic puncture);

15. Infection, ulceration and unhealed wound on the skin where the electrode is applied;

16. Currently participating in other antitumor therapy clinical trials;

17. Implantable electronic medical devices, such as pacemakers;

18. Chest and abdomen have implanted metal materials of medical instruments, such as bone nails;

19. Allergic to conductive hydrogels or medical adhesives;

20. Pregnant or trying to become pregnant or breastfeeding;

21. Poor compliance or other factors as judged by the investigator were not appropriate for the study.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Disease Progression
• Lung Neoplasms
• Non-small Cell Lung Cancer (NSCLC)

Intervention

Device:
• Tumor treating fields(EFE-P100)
Device: Tumor treating fields(EFE-P100) Subjects will use EFE-P100 until disease progression or for a maximum of 24 months.

Drug:
• Docetaxel injection
Drug: Docetaxel injection Subjects will receive Docetaxel injection until disease progression or for a maximum of 24 months.

Locations

Country	Name	City	State
China	Shanghai Pulmonary Hospital	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival (PFS)	Progression-free survival is defined as the time from the start of treatment with Tumor Treating Fields(EFE-P100) and Docetaxel until the first documentation of disease progression or death due to any cause, whichever occurs first	Up to 2 years
Secondary	Number of participants with adverse events (AEs)	Will be defined as the incidence, frequency and severity of adverse events (AEs) noted in patients treated with study treatments	The whole study period,an average of 2 year
Secondary	Objective response rate (ORR)	ORR is defined as the proportion of subjects with confirmed CR or PR, based on RECIST v1.1.	Up to 2 years
Secondary	Overall survival (OS)	From date of enrollment until the date of death from any cause	up to 12 months after the last study treatment
Secondary	12-month OS rate	12-month Overall survival rate	12 months
Secondary	Progression Free Survival rate at 6 months	The analysis will be estimated proportions of patients who are progression-free at 6 months based on the RECIST 1.1 criteria following the time of enrollment	6 months